PURASORB PLDL 8058 Medical Device L/DL-Lactide Copolymer is a bulk resorbable polymer supplied by Corbion for implantable device components and controlled-release matrices. The grade designation identifies an 80/20 L-lactide-to-DL-lactide ratio and a mid-point inherent viscosity of 5.8 dL/g determined in chloroform at 25 °C and a polymer concentration of 0.1 g/dL; lot-specific values are controlled by the manufacturer certificate of analysis. The racemic DL-lactide comonomer disrupts stereoregular packing of poly(L-lactide), producing a low-crystallinity matrix with a glass transition near 55–60 °C and no practical crystalline melting point under routine processing conditions. The material is manufactured under an ISO 13485 quality management system, and final-device biological evaluation follows ISO 10993-1:2018. Because the grade is supplied as pellets or granules, downstream converters are responsible for validated drying, melt processing, and terminal sterilisation steps.

Specification envelope and release analytics

Release documentation for this grade typically includes the following parameters. Product-specific data are verified against lot certificates of analysis; the table consolidates representative release limits from medical-grade lactide copolymer documentation rather than standing purchase specifications.

Residual monomer, water, and tin are process-critical variables because they influence hydrolytic stability during storage and melt-processing reproducibility. A water content above 0.5 wt% can accelerate viscosity loss during extrusion; the certificate of analysis therefore functions as the release boundary, not a general technical brochure value.

Before melt conversion, the polymer must be dried to a residual moisture level below 0.025 wt% to suppress hydrolysis-induced chain scission. Production-scale dryers should deliver a dew point of at least -40 °C and maintain hopper residence between 4 h and 12 h at 80–100 °C; vacuum ovens operating below 50 mbar are equally effective for small lots. At relative humidity above 60%, dried pellets reabsorb moisture within minutes, so sealed transfer lines or dry-air conveying are required between the dryer and the feed throat. Failure to control moisture typically appears as viscosity reduction of 0.2–0.5 dL/g or more after processing, with corresponding loss of mechanical strength in the finished device. This is a well-documented failure mode on production extrusion lines processing high-inherent-viscosity lactide copolymers.

What processing boundaries govern melt fabrication of high-inherent-viscosity PLDL 8058?

Melt-processing trials on high-torque twin-screw extruders indicate that the high molecular weight of PLDL 8058 translates into elevated melt pressure and shear heating. Extrusion is typically carried out on a co-rotating twin-screw line with an L/D ratio of 32:1 or higher, using modular screw elements with gentle kneading blocks to limit local temperature spikes. Barrel settings from 165 °C to 200 °C are maintained, with the die temperature held near 190 °C; melt temperatures above 240 °C initiate random chain scission and lactide reformation, while temperatures below 160 °C result in incomplete plastication and screw overload. Because the material is amorphous or low-crystallinity under fast cooling, rapid quenching on a chilled belt or into water at 10–20 °C is used to prevent uncontrolled crystallite formation. Residence time is kept below 10 min; longer residence broadens molecular weight distribution and reduces inherent viscosity.

Capillary rheometry at 180 °C and 200 °C brackets apparent shear viscosity in the range of 10²–10³ Pa·s at shear rates from 10 s⁻¹ to 1000 s⁻¹; the melt is shear-thinning. Published data for this specific grade is limited, so these values are literature-bracketed rather than product-certified. For injection molding, clamp force and shot size must account for the polymer’s high viscosity; mold temperatures of 15–25 °C and packing pressures in the 600–1000 bar range are common for small implant parts, though published data for this specific configuration is limited.

Applications for PLDL 8058 are concentrated in load-bearing resorbable fixation hardware, including interference screws, suture anchors, and craniofacial plates, where the high inherent viscosity contributes to melt strength and mechanical integrity during the early healing period. The material is also specified for long-acting injectable microspheres and implantable rods when release periods of several months are required. Mechanical evaluation of absorbable fixation plates and screws is conducted under ASTM F2502-17, while in vitro drug release from delivery systems is assessed using USP 711 apparatus 2 or 4 depending on the dosage form. Because PLDL 8058 is a bulk copolymer, final-device processing history, sterilisation dose, and storage humidity shift the performance envelope; therefore, design verification must be repeated on production-equivalent parts.

Hydrolysis of the ester backbone controls the resorption time of PLDL 8058. The 80/20 L-lactide/DL-lactide ratio places the material in an intermediate degradation window: it is slower than 50/50 lactide/glycolide copolymers, which degrade in weeks to months, and faster than semi-crystalline PLLA homopolymer, which can require more than 24 months for substantial mass loss in thick sections. The reduced crystallinity of PLDL 8058 limits the autocatalytic two-stage degradation associated with crystalline PLLA; water uptake is more uniform, and amorphous regions do not leave persistent crystalline debris. In vitro degradation studies for this class of copolymer typically use phosphate-buffered saline at 37 °C and pH 7.4 with mass loss, inherent viscosity, and pH monitoring per ISO 13781:2017 or equivalent laboratory protocols. Published data for this specific configuration is limited; therefore, final resorption rates must be measured on the actual device geometry and sterilisation state.

Comparative data for polymer-class selection are summarised in the following table. The values are literature-bracketed for the class; they are not product-specific release specifications.

Compared with PLLA homopolymer grades, PLDL 8058 has lower tensile modulus and yield strength in the as-processed state because the DL-lactide comonomer suppresses crystallisation. A semi-crystalline PLLA screw may retain a flexural modulus above 3 GPa, whereas the amorphous 80/20 copolymer typically exhibits values nearer 2 GPa; actual values depend on molecular orientation, annealing, and test method per ISO 178 or ASTM D790-17. Compared with lactide/glycolide copolymers, PLDL 8058 has a longer degradation window and lower acid-burst autocatalysis, making it less aggressive in confined implant sites. Compared with lower-inherent-viscosity grades within the PURASORB PLDL range, the 5.8 dL/g mid-point provides higher melt strength and improved toughness for load-bearing components, but also narrows the processing window by increasing melt pressure and shear heating. This trade-off is the primary selection criterion when replacing PLLA homopolymer or faster-resorbing PLGA in a device design.

When terminal sterilisation is selected for implantable components

Sterilisation route selection changes the molecular-weight retention of PLDL 8058. Ethylene oxide processing according to ISO 11135:2014 can be used with aeration to reduce residual ethylene oxide and ethylene chlorohydrin; the low glass transition temperature requires chamber temperatures not exceeding 45 °C to avoid part deformation. Gamma irradiation at doses of 25 kGy to 40 kGy in accordance with ISO 11137-2:2013 causes free-radical chain scission and measurable loss of inherent viscosity; post-irradiation testing of inherent viscosity and monomer content is therefore mandatory before release. Electron-beam irradiation produces similar chain-scission effects but with lower oxidative side-product formation if the dose is fractionated. Hydrogen peroxide plasma is generally limited to surface sterilisation and may require validated penetration for porous or bulk implant geometries. No single sterilisation method is inherently compatible across all device designs; the final device manufacturer must establish the sterilisation dose and residual limits under the applicable ISO 11135 or ISO 11137 series.